Clinical trials: MF
Myelofibrosis，MF
Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have Thrombocytopenia
We hypothesize that pacritinib leads to modification of the myelofibrosis (MF) disease phenotype, especially related to BM fibrosis and cytopenias; due potentially to its dual effect as an inhibitor of the JAK and NFκB pathways…
- Trial name
- PACRIMYEL (NCT07394153)
- Testing
- Pacritinib
- Where
- 13 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Grupo Español de Enfermedades Mieloproliferativas Crónicas PH Negativas
Myelofibrosis
Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis
This is a phase Ib study with the primary purpose is to estimate the MTD and/or RDE for the triple combination of PIM447, formerly LGH447, plus ruxolitinib and LEE011 as well as for the doublets, PIM447 plus ruxolitinib, and…
- Trial name
- NCT02370706
- Testing
- PIM447, Ruxolitinib, LEE011
- Where
- 9 sites in Australia, Canada and 6 more
- Volunteers
- 15 people
- Sponsor
- Novartis Pharmaceuticals
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
The purpose of this study is to determine the safety and tolerability of orally administered NS-018 in patients with Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (post-PV MF), or Post-essential…
- Conditions
- Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis
- Trial name
- NCT01423851
- Testing
- NS-018
- Where
- 9 sites in United States
- Volunteers
- 77 people
- Sponsor
- NS Pharma, Inc.
Cutaneous T Cell Lymphoma, Mycosis Fungoides/Sezary Syndrome
A Trial Assessing the Effect of Pembrolizumab Combined with Radiotherapy in Patients with Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS)
Trial Subjects (patients), will receive single infusions of pembrolizumab every 3 weeks until disease progression or unacceptable toxicity develops. They will receive radiotherapy at week 12.
- Trial name
- PORT (NCT03385226)
- Testing
- Pembrolizumab, Radiotherapy
- Where
- 11 sites in United Kingdom
- Volunteers
- 46 people
- Sponsor
- University College, London
Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome
Study of Photopheresis in the Treatment of Erythrodermic MF and SS
PROMPT: a study of photopheresis for the treatment of erythrodermic mycosis fungoides and Sézary syndrome For this study, the investigators invite patients suffering from erythrodermic mycosis fungoides (MF) and Sézary syndrome…
- Trial name
- PROMPT (NCT03563040)
- Testing
- Methoxsalen, THERAKOS CELLEX Photopheresis System
- Where
- Switzerland
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Cutaneous T-Cell Lymphoma/Mycosis Fungoides
PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma
To assess the blood levels of hypericin and any electrocardiogram (ECG) changes during 8 weeks of HyBryte (topical hypericin ointment) photodynamic therapy.
- Trial name
- NCT05380635
- Testing
- Hypericin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Soligenix
Myelofibrosis
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Myelofibrosis With Myeloid Metaplasia
Defects in the apoptotic process can lead to the onset of cancer by allowing cells to grow unchecked when an oncogenic signal is present.
- Trial name
- NCT00360035
- Testing
- Obatoclax mesylate (GX15-070MS)
- Where
- 7 sites in United States, Canada
- Volunteers
- 22 people
- Sponsor
- Gemin X
Cystic Fibrosis
A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes
This study will evaluate the efficacy and safety of elexacaftor (ELX) / tezacaftor (TEZ) / ivacaftor (IVA) triple combination (TC) in subjects 6 through 11 years of age with cystic fibrosis (CF) who are heterozygous for F508del…
- Trial name
- NCT04353817
- Testing
- ELX/TEZ/IVA, IVA
- Where
- 34 sites in Australia, Canada and 8 more
- Volunteers
- 121 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Primary Myelofibrosis, Polycythemia Vera
A Phase 2 Study of RO7490677 In Participants With Myelofibrosis
RO7490677 is an investigational drug that is being developed for possible use in the treatment of myelofibrosis (MF), a disease in which the bone marrow, which is the organ in the body that makes blood cells, is replaced by…
- Conditions
- Primary Myelofibrosis, Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis
- Trial name
- NCT01981850
- Testing
- RO7490677, Ruxolitinib
- Where
- 23 sites in United States, Canada and 6 more
- Volunteers
- 125 people
- Sponsor
- Hoffmann-La Roche
Myelofibrosis (MF), HSCT
Gecacitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis
The investigators evaluate the efficacy and safety of Gecacitinib in patients with myelofibrosis (MF) before, during, and after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- Trial name
- CONTINUUM-MF (NCT07471503)
- Testing
- Gecacitinib (also known as Jaktinib)
- Volunteers
- 39 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Myelofibrosis (MF)
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis
This is a Phase 2 open-label, multicenter study evaluating tolerability and efficacy of navitoclax alone or when added to ruxolitinib in participants with myelofibrosis.
- Trial name
- REFINE (NCT03222609)
- Testing
- Ruxolitinib, Navitoclax
- Where
- 91 sites in United States, Australia and 12 more
- Volunteers
- 191 people
- Sponsor
- AbbVie
Mild Asthma
Study of QMF149 (150/80 µg) Compared With MF Twisthaler® (200 µg) in Patients With Asthma
The purpose of the trial was to evaluate efficacy and safety of QMF149 150/80 microgram o.d. delivered via Concept1 compared to MF 200 microgram o.d., delivered via Twisthaler® in terms of lung function and symptom control in…
- Trial name
- NCT02892344
- Testing
- QMF149 150/80 μg, MF 200 μg
- Where
- 123 sites in Bulgaria, Chile and 20 more
- Volunteers
- 802 people
- Sponsor
- Novartis Pharmaceuticals
Primary Myelofibrosis
A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory…
- Trial name
- NCT04446650
- Testing
- Fedratinib
- Where
- 21 sites in Japan
- Volunteers
- 31 people
- Sponsor
- Bristol-Myers Squibb
Cutaneous T-Cell Lymphoma, Mycosis Fungoides (MF)
Efficacy and Safety of Benvitimod Cream in Cutaneous T-Cell Lymphoma
Background: CTCL is a rare type of non-Hodgkin lymphoma that primarily affects the skin, causing red patches, plaques, and severe itching.
- Trial name
- BEST-CTCL (NCT07658924)
- Testing
- Benvitimod Cream
- Volunteers
- 35 people
- Sponsor
- Peking University First Hospital
Myelofibrosis
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib
This is a phase 1b/2 study of KRT-232 combined with ruxolitinib in subjects with MF who have a suboptimal response after at least 18 weeks of treatment with ruxolitinib.
- Trial name
- NCT04485260
- Testing
- KRT-232, Ruxolitinib
- Where
- 38 sites in United States, Australia and 7 more
- Volunteers
- 36 people
- Sponsor
- Kartos Therapeutics, Inc.
Solid Tumors
Study of INCB053914 in Subjects With Advanced Malignancies
This is an open-label, dose-escalation study of the proviral integration site of Moloney murine leukemia virus (PIM) kinase inhibitor INCB053914 in subjects with advanced malignancies. The study will be conducted in 4 parts.
- Trial name
- NCT02587598
- Testing
- INCB053914, I-DAC (Intermediate dose cytarabine), Azacitidine
- Where
- 19 sites in United States
- Volunteers
- 97 people
- Sponsor
- Incyte Corporation
Gastric Cancer, Neoplasm Metastasis
A Study of 5-FU Versus MTX+5-FU in Gastric Cancer With Peritoneal Metastasis
To develop effective chemotherapy regimen against gastric cancer with peritoneal metastasis
- Trial name
- NCT00149201
- Testing
- 5-FU continuous infusion, MTX + 5-FU sequential therapy
- Where
- 34 sites in Japan
- Volunteers
- 160 people
- Sponsor
- Japan Clinical Oncology Group
Leukemia
An Open-label Phase II Study of Lorvotuzumab Mertansine
The goal of this clinical research study is to learn if lorvotuzumab mertansine can help to control blood cancers that have the CD56 tumor marker. The safety of this drug will also be studied.
- Trial name
- NCT02420873
- Testing
- Lorvotuzumab Mertansine (IMGN901)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- M.D. Anderson Cancer Center
Myeloproliferative Disorders
Study of SB939 in Subjects With Myelofibrosis
The goal of this clinical research study is to learn if SB939 can help to control myelofibrosis. The safety of this drug will also be studied.
- Trial name
- NCT01200498
- Testing
- SB939
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- M.D. Anderson Cancer Center
Pharyngitis
Efficacy and Tolerability of Ambroxol Lozenge 20 mf in Relieving Pain of Sore Throat in Pat. With Acute/Viralpharyngitis
The purpose of this trial is to investigate efficacy and tolerability of lozenges containing 20 mg a mbroxol hydrochloride (Mucoangin?) relative to lozenges containing placebo and lozenges containing 3 mg benzocaine in relieving…
- Trial name
- NCT00148499
- Testing
- Ambroxol hydrochloride (Mucoangin?), benzocaine
- Where
- 14 sites in Romania, Ukraine
- Volunteers
- 751 people
- Sponsor
- Boehringer Ingelheim